

**Drug Disposition: Drug Disposition & Malignant Hypothermia**

- A-518** Room H, 10/16/2000 9:00 AM - 11:00 AM (PS)  
**Prospective Validation of the Context Sensitive Half Times for Propofol** *Matthew T. Chan, FANZCA; P.T. Chui, FANZCA; Y.H. Tam, M Phil; Tony Gin, MD, Anaesthesia and Intensive Care, Chinese University of Hong Kong, Hong Kong.* The calculated context sensitive half times for propofol closely predicts the actual decline of plasma concentration.
- A-519** Room H, 10/16/2000 9:00 AM - 11:00 AM (PS)  
**A Pilot Study of Oral Transmucosal Etomidate in Volunteers** *Talmage D. Egan, M.D.; Carl Roland, Pharm.D.; Julia L. White, RN,BS; Mason A. Gay, BS; Steven E. Kern, Ph.D., Department of Anesthesiology, University of Utah, Salt Lake City, UT, United States.* We studied the relative bioavailability of OTS-Etomidate in a group of 12 volunteers as a proof of concept study for providing sedation with the OTS product.
- A-520** Room H, 10/16/2000 9:00 AM - 11:00 AM (PS)  
**In-Vivo Effects of the Serotonin-2 Receptor Agonist DOI on Anesthetized Swine Susceptible for Malignant Hyperthermia** *Marko Fiege, MD; Frank Wappler, MD; Jens Scholz, MD; Ralf Weissborn, MD; Jochen Schulte am Esch, MD, Department of Anesthesiology, University Hospital Eppendorf, Hamburg, Germany.* MH-typical reactions to DOI in malignant hyperthermia susceptible swine are stress-independent.
- A-521** Room H, 10/16/2000 9:00 AM - 11:00 AM (PS)  
**Pharmacokinetics of TCI-Propofol in Parkinson's Disease Patients Undergoing Sub-Thalamic Deep Brain Stimulation Implantation** *Pedro L. Gambus, MD; Inaki F. Troconiz, PhD; Ricard Valero, MD; Enrique Carrero, MD; Neus Fabregas, MD, Anesthesiology, Hospital Clinic, Univ. Barcelona, Barcelona, Spain.* Propofol-TCI kinetic model is less accurate and is biased for sedation of Parkinson patients.
- A-522** Room H, 10/16/2000 9:00 AM - 11:00 AM (PS)  
**Preoperative  $\beta$ -Blockade Has a Protective Effect on Epinephrine-Induced Myocardial Ischemia in Patients Undergoing Coronary Surgery** *Michael Gunnicker, MD; Michael T. Nusch, MD; Goran Pavlakovic, MD; Matthias Brinkmann, MD, Dept. of Anesthesiology and Intensive-Care, University Hospital, Essen, Germany.*  $\beta$ -Blockade avoids myocardial lactate generation after epinephrine.
- A-523** Room H, 10/16/2000 9:00 AM - 11:00 AM (PS)  
**Lack of Involvement of CYP2B and 2C in the Metabolism of Midazolam: Kinetic Analysis and Inhibition Study with Monoclonal Antibodies** *Naoya Hamaoka; Yutaka Oda; Ichiro Hase; Tatsuo Nakamoto; Akira Asada, Anesthesiology and Intensive Care Medicine, Osaka City University, Osaka, Japan.* Cytochrome P450 2B and 2C are not involved in the metabolism of midazolam
- A-524** Room H, 10/16/2000 9:00 AM - 11:00 AM (PS)  
**Noninvasive Estimation of the Recirculatory Pharmacokinetics of a Marker of the Intravascular Space during Liver Transplantation** *Thomas K. Hentborn, MD; Susan Mandell, MD, PhD, Anesthesiology and Pharmaceutical Sciences, University of Colorado Health Sciences Center, Denver, CO, United States.* The peripheral circuit with the long mean transit time consists largely of the splanchnic circulation.
- A-525** Room H, 10/16/2000 9:00 AM - 11:00 AM (PS)  
**Evidence That the Fentanyl Blood-Brain-Barrier Transporter Is pKa-Specific** *Thomas K. Hentborn, MD; Xiangdong Yan, PhD; Lawrence Ng, PhD, Anesthesiology and Pharmaceutical Sciences, University of Colorado Health Sciences Center, Denver, CO, United States.* The active transport of fentanyl into brain endothelial cells is more potently inhibited by basic drugs than by acidic drugs.
- A-526** Room H, 10/16/2000 9:00 AM - 11:00 AM (PS)  
**The Effects of Propofol on Platelet Aggregation** *Hideo Hirakata, MD; Masami Sugahara, MD; Kazuhiko Fukuda, MD, Anesthesia, Kyoto University Hospital, Kyoto, Japan.* Propofol and Diprivan® have different effects on platelet aggregation and IP<sub>3</sub> formation, although Intralipid® did not affect platelet IP<sub>3</sub> formation.
- A-527** Room H, 10/16/2000 9:00 AM - 11:00 AM (PS)  
**Influence of Sufentanil Concentration on Propofol Requirement and Recovery Times during Thyroid Surgery** *Malik Hofufani, MD; Elisabeth Hentgen, MD; Florent Capron, MD; Jean-Marc Ropars; Valerie Billard, MD, Anesthésie, Institut Gustave Roussy, Villejuif, France*
- A-528** Room H, 10/16/2000 9:00 AM - 11:00 AM (PS)  
**Pharmacokinetics of Liposomal  $\Delta^9$ -Tetrahydrocannabinol (THC) Delivered through the Lungs** *Orlando R. Hung, MD; Pang Shek, Ph.D.; Peter Tikuisis, Ph.D.; Jiri Zamecnik, Ph.D., Anesthesia, Dalhousie University, Halifax, Nova Scotia, Canada*
- A-529** Room H, 10/16/2000 9:00 AM - 11:00 AM (PS)  
**Effects of Parecoxib, a Parenteral COX-2 Specific Inhibitor, on the Disposition of Midazolam** *Andra Ibrahim, MD; Aziz Karim, PhD; Jennifer Feldman, BS; Evan Kharasch, MD, PhD, Anesthesiology, University of Washington, Seattle, WA, United States*
- A-530** Room H, 10/16/2000 9:00 AM - 11:00 AM (PS)  
**Effects of Parecoxib, a Parenteral COX-2 Specific Inhibitor, on the Disposition of Propofol** *Andra Ibrahim, MD; Sang Park, PhD; Jennifer Feldman, BS; Evan Kharasch, MD, PhD, Anesthesiology, University of Washington, Seattle, WA, United States*
- A-531** Room H, 10/16/2000 9:00 AM - 11:00 AM (PS)  
**The Elimination of Alfentanil Is Decreased by Propofol** *Harald Ihmsen, M.Sc.; Sven Albrecht, M.D.; Jorg Fechner, M.D.; Werner Hering, M.D.; Jurgen Schuttler, M.D., Department of Anesthesiology, University of Erlangen-Nuremberg, Erlangen, Germany.* Pharmacokinetics of alfentanil during TIVA with propofol was studied in 20 patients. Clearance of alfentanil was reduced by 38%.
- A-532** Room H, 10/16/2000 9:00 AM - 11:00 AM (PS)  
**PK/PD Analysis of Etomidate Given across the Buccal Mucosa** *Steven E. Kern, Ph.D.; Carl Roland, Pharm.D.; Julia L. White, RN,BS; Mason A. Gay, BS; Talmage D. Egan, M.D., Department of Anesthesiology, University of Utah, Salt Lake City, UT, United States.* We studied the kinetics and dynamics of a transmucosal etomidate in volunteers using multiple arterial blood samples, the OAA/S score and the BIS index.
- A-533** Room H, 10/16/2000 9:00 AM - 11:00 AM (PS)  
**Intrarenal Metabolism and Toxicity of Methoxyflurane** *Evan D. Kharasch, MD, PhD; Richard A. Zager, MD; Candy Hsieh, BS; Eric Flamoe, BS, Anesthesiology, University of Washington, Seattle, WA, United States*